Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype
A. N. Cvrljevic, U. Butt, K. Huhtinen, T. Gronroos, C. Bockelman, H. Lassus, K. Kaipio, A. Ristimaki, T. Arsiola, T. D. Laajala, D. Connolly, O. Carpen, J. Pouwels, J. Westermarck
The paper identifies ovarian cancers with low CIP2A expression as a subtype sensitive to APR-246, a ROS-inducing compound, and shows CIP2A's role in modulating NF-kB activity and drug response.
bioRxiv · Mar 31, 2021Cancer Biology